Targeted Next-generation Sequencing Identified Novel Mutations in Triple-negative Myeloproliferative Neoplasms

Overview

Journal Med Oncol

Publisher Springer

Specialty Oncology

Date 2017 Apr 9

PMID 28389907

Citations 25

Authors

Yu-Cheng Chang

Huan-Chau Lin

Yi-Hao Chiang

Caleb Gon-Shen Chen

Ling Huang

Wei-Ting Wang

Chun-Chia Cheng

Johnson Lin

Yi-Fang Chang

Ming-Chih Chang

Ruey-Kuen Hsieh

Shu-Jen Chen

Ken-Hong Lim

Yuan-Yeh Kuo

Affiliations

Soon will be listed here.

Abstract

Mutations in JAK2, MPL and CALR genes have been identified in the majority of myeloproliferative neoplasm (MPN) patients, and patients negative for these three mutations are the so-called triple-negative (TN) MPN. In this study, we examined the mutational profiles of 16 triple-negative MPN patients including 7 essential thrombocythemia (ET), 1 primary myelofibrosis and 8 polycythemia vera (PV). Targeted next-generation sequencing was performed using the ACTOnco Comprehensive Cancer Panel (Ion AmpliSeq Comprehensive Cancer Panel, Life Technologies) to target all coding exons of 409 cancer-related genes. Overall, 30 nonsynonymous somatic mutations were detected in 12 (75%) patients with a range of 1-5 mutations per sample. Notably, one ET patient was found to have JAK2V617F and KITP551L mutations at very low allele frequency. One MPLP70L and 1 MPLM602T mutations were identified each in 1 ET and 1 PV, respectively. Other recurrent mutations were also identified including KMT2C, KMT2D, IRS2, SYNE1, PDE4DIP, SETD2, ATM, TNFAIP3 and CCND2. In addition, germline mutations were also found in some cancer-related genes. Copy number changes were rare in this cohort of TN MPNs. In conclusion, both somatic and germline mutations can be detected in TN MPN patients.

Citing Articles

Two Novel Genetic Variants Involved in the Oxygen Sensing Pathway in JAK2-unmutated Erythrocytosis.

Ma Q, Hu R, Hui W, Zhao H, Zou D, Liu Y Biochem Genet. 2024; .

PMID: 38568374 DOI: 10.1007/s10528-024-10752-2.

Molecular Genetic Profile of Myelofibrosis: Implications in the Diagnosis, Prognosis, and Treatment Advancements.

Verma T, Papadantonakis N, Peker Barclift D, Zhang L Cancers (Basel). 2024; 16(3).

PMID: 38339265 PMC: 10854658. DOI: 10.3390/cancers16030514.

Obesity and Leukemia: Biological Mechanisms, Perspectives, and Challenges.

Tsilingiris D, Vallianou N, Spyrou N, Kounatidis D, Christodoulatos G, Karampela I Curr Obes Rep. 2023; 13(1):1-34.

PMID: 38159164 PMC: 10933194. DOI: 10.1007/s13679-023-00542-z.

Molecular landscape of the gene in chronic myeloproliferative neoplasm patients from the state of Amazonas, Brazil.

Torres D, Barbosa Alves E, Araujo de Sousa M, Laranjeira W, Paes J, Alves E Biomed Rep. 2023; 19(6):98.

PMID: 37954635 PMC: 10633817. DOI: 10.3892/br.2023.1680.

PDE4DIP contributes to colorectal cancer growth and chemoresistance through modulation of the NF1/RAS signaling axis.

Pan R, Dai J, Liang W, Wang H, Ye L, Ye S Cell Death Dis. 2023; 14(6):373.

PMID: 37355626 PMC: 10290635. DOI: 10.1038/s41419-023-05885-y.

References

Klampfl T, Gisslinger H, Harutyunyan A, Nivarthi H, Rumi E, Milosevic J . Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med. 2013; 369(25):2379-90. DOI: 10.1056/NEJMoa1311347. View

Levine R, Wadleigh M, Cools J, Ebert B, Wernig G, Huntly B . Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005; 7(4):387-97. DOI: 10.1016/j.ccr.2005.03.023. View

Cabagnols X, Favale F, Pasquier F, Messaoudi K, Defour J, Ianotto J . Presence of atypical thrombopoietin receptor (MPL) mutations in triple-negative essential thrombocythemia patients. Blood. 2015; 127(3):333-42. DOI: 10.1182/blood-2015-07-661983. View

Milosevic Feenstra J, Nivarthi H, Gisslinger H, Leroy E, Rumi E, Chachoua I . Whole-exome sequencing identifies novel MPL and JAK2 mutations in triple-negative myeloproliferative neoplasms. Blood. 2015; 127(3):325-32. PMC: 4752213. DOI: 10.1182/blood-2015-07-661835. View

Li S, Kralovics R, De Libero G, Theocharides A, Gisslinger H, Skoda R . Clonal heterogeneity in polycythemia vera patients with JAK2 exon12 and JAK2-V617F mutations. Blood. 2008; 111(7):3863-6. DOI: 10.1182/blood-2007-09-111971. View

Tefferi A . Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. Leukemia. 2010; 24(6):1128-38. PMC: 3035972. DOI: 10.1038/leu.2010.69. View

Lim K, Lin H, Chen C, Wang W, Chang Y, Chiang Y . Rapid and sensitive detection of CALR exon 9 mutations using high-resolution melting analysis. Clin Chim Acta. 2014; 440:133-9. DOI: 10.1016/j.cca.2014.11.011. View

Kralovics R, Passamonti F, Buser A, Teo S, Tiedt R, Passweg J . A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005; 352(17):1779-90. DOI: 10.1056/NEJMoa051113. View

Kilpivaara O, Levine R . JAK2 and MPL mutations in myeloproliferative neoplasms: discovery and science. Leukemia. 2008; 22(10):1813-7. DOI: 10.1038/leu.2008.229. View

10.

Baxter E, Scott L, Campbell P, East C, Fourouclas N, Swanton S . Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005; 365(9464):1054-61. DOI: 10.1016/S0140-6736(05)71142-9. View

11.

Chao A, Chang T, Lapke N, Jung S, Chi P, Chen C . Prevalence and clinical significance of BRCA1/2 germline and somatic mutations in Taiwanese patients with ovarian cancer. Oncotarget. 2016; 7(51):85529-85541. PMC: 5356755. DOI: 10.18632/oncotarget.13456. View

12.

Pikman Y, Lee B, Mercher T, McDowell E, Ebert B, Gozo M . MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med. 2006; 3(7):e270. PMC: 1502153. DOI: 10.1371/journal.pmed.0030270. View

13.

Pardanani A, Lasho T, Finke C, Oh S, Gotlib J, Tefferi A . LNK mutation studies in blast-phase myeloproliferative neoplasms, and in chronic-phase disease with TET2, IDH, JAK2 or MPL mutations. Leukemia. 2010; 24(10):1713-8. DOI: 10.1038/leu.2010.163. View

14.

Nangalia J, Massie C, Baxter E, Nice F, Gundem G, Wedge D . Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med. 2013; 369(25):2391-2405. PMC: 3966280. DOI: 10.1056/NEJMoa1312542. View

15.

James C, Ugo V, Le Couedic J, Staerk J, Delhommeau F, Lacout C . A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005; 434(7037):1144-8. DOI: 10.1038/nature03546. View

16.

Tefferi A, Pardanani A . Myeloproliferative Neoplasms: A Contemporary Review. JAMA Oncol. 2015; 1(1):97-105. DOI: 10.1001/jamaoncol.2015.89. View